Latest News

Siponimod receives FDA approval for SPMS


Siponimod (Mayzent), a second-generation sphingosine-1-phosphate (S1P) receptor modulator, has received approval by the U.S. Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome (CIS), relapsing-remitting MS and active secondary-progressive MS (SPMS). Read More


Pre-AAN Survey


NeuroSens will be reporting from the American Academy of Neurology (AAN) annual meeting, with daily reports and special post-meeting coverage of key topics. Read More